1. Considered and approved the Un-audited financial results of the company for the quarter ended 30th June 2025. 2. Appointment of M/s. SBR & Co. LLP, Company Secretaries (LLP No. AAO-9057) ....
Price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Awaiting price reaction for this filing.
Genomic Valley Biotech Ltd's board met on 7th August 2025 and approved the unaudited financial results for Q1FY26 (quarter ended 30 June 2025). Revenue for the quarter was negligible at Rs. 616, with total expenses of Rs. 5.53 lakh and a profit after tax of Rs. 2.47 lakh, compared to a loss of Rs. 8.15 lakh in the previous quarter. The board also appointed M/s. SBR & Co. LLP as Secretarial Auditors for FY 2025-2030 and Mr. Navjyoti Kumar Jha as Internal Auditor for FY 2025-26. Additionally, Mr. Yogesh Agrawal was re-appointed as Chairman & Managing Director for a further five years effective 7 September 2025. The statutory auditor (Andros & Co.) issued an unqualified limited review report on the results.
This is a routine quarterly board outcome with no major surprises. The CMD re-appointment of a promoter-director provides leadership continuity. The extremely small revenue and profit base indicate a micro-cap company with limited operating activity, so these results are unlikely to move the stock meaningfully on their own.